Edinburgh, UK – 27/07/23 – Nodus Oncology, an emerging biotech company which is focused on developing first and best-in-class molecules inhibiting novel DDR targets, is pleased to announce the appointment of Dr Thomas Wirth as Chief Business Officer.
“The appointment of Thomas is a great addition to the Nodus team” said Ian Waddell, CEO of Nodus Oncology. Thomas is a qualified and result-driven professional with an interdisciplinary background and strong business acumen. He has extensive experience in establishing companies, working closely with investors, Boards of Directors, and executive leadership.
As a Founder and formerly CSO of Aurealis Therapeutics, he has spearheaded the Research and Development of a topical cell therapy for diabetic foot ulcers. He also chaired the Board of Celloryx AG, an oncology-focused gene therapy company. Additional career highlights include working as a Research Director at Ark Therapeutics, wherein he established preclinical proof-of-concept for two oncological gene therapy products as well as working 12 years as a Senior Research Scientist for the University of Eastern Finland, where he conducted research on the immunological environment of brain tumours and was granted a docentship based on his scientific achievements. Thomas has a history of defining roadmaps and translating innovative ideas into strategic products. He is well-versed in building and maintaining strong relationships with internal and external stakeholders at all levels, leading and motivating teams to bring new and effective treatments to patients.
